MARKET

SNDX

SNDX

Syndax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.48
+0.42
+2.33%
Opening 10:43 06/24 EDT
OPEN
18.32
PREV CLOSE
18.06
HIGH
18.74
LOW
18.13
VOLUME
62.94K
TURNOVER
--
52 WEEK HIGH
27.85
52 WEEK LOW
13.02
MARKET CAP
891.63M
P/E (TTM)
-9.9120
1D
5D
1M
3M
1Y
5Y
Syndax Pharmaceuticals: Return On Capital Employed Insights
In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million. Syndax Pharmaceuticals collected $380.00 thousand in revenue during Q4, but ...
Benzinga · 6d ago
Buy These 2 Stocks Before They Jump Over 60%, Says Analyst
We’re in interesting times, there’s no doubt about that. The COVID crisis is receding, the economic reopening is proceeding apace – but there are inflationary worries. The Biden Administration is committed to a heavy spending program, including generous ex...
TipRanks · 06/08 00:38
Return On Capital Employed Overview: Syndax Pharmaceuticals
In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million. In Q4, Syndax Pharmaceuticals brought in $380.00 thousand in sales but lost ...
Benzinga · 06/03 15:13
Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Gol...
PR Newswire · 06/03 11:00
Canopy upgraded on economy reopening, Xeris PT cut on acquisition news, and more in analyst action
Canopy set for growth on Canadian economy re-openingWhile not expecting a significant Q4 2021 beat for Canopy Growth (CGC) on June 1, MKM expects a turnaround as the Canadian economy
Seekingalpha · 05/25 14:59
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
 
Benzinga · 05/25 14:02
Citigroup Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $24
Citigroup analyst Yigal Nochomovitz initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price Target of $24.
Benzinga · 05/25 10:59
--Citigroup Starts Syndax Pharmaceuticals at Buy With $24 Price Target
MT Newswires · 05/25 06:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNDX. Analyze the recent business situations of Syndax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNDX stock price target is 28.00 with a high estimate of 32.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 175
Institutional Holdings: 48.88M
% Owned: 101.31%
Shares Outstanding: 48.25M
TypeInstitutionsShares
Increased
55
7.07M
New
13
2.09M
Decreased
44
4.03M
Sold Out
25
3.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.77%
Pharmaceuticals & Medical Research
+1.54%
Key Executives
Non-Executive Chairman/Independent Director
Dennis Podlesak
President/Chief Operating Officer/Director
Michael Metzger
Chief Executive Officer/Director
Briggs Morrison
Chief Financial Officer
Daphne Karydas
Senior Vice President/General Counsel/Secretary
Luke Albrecht
Senior Vice President
Michael Meyers
Chief Scientific Officer
Peter Ordentlich
Independent Director
Fabrice Egros
Independent Director
Jennifer Jarrett
Independent Director
Keith Katkin
Independent Director
Pierre Legault
Independent Director
William Meury
No Data
  • All
  • Financials
  • Insiders
More
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, is a once-weekly, oral, small molecule, Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer. The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. It is also developing SNDX-6352, a monoclonal antibody targeting the colony stimulating factor-1 receptor.

Webull offers kinds of Syndax Pharmaceuticals Inc stock information, including NASDAQ:SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.